{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-262210","form_type":"8-K","ticker":"ELVN","cik":"0001672619","company_name":"Enliven Therapeutics, Inc.","filed_at":"2022-10-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.654487+00:00","generated_at":"2026-06-23T03:51:26.432992+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Imara to merge with Enliven; Enliven stockholders to own ~84% of combined company","bullets":["Enliven valued at $324.6M plus $164.5M financing; Imara valued at net cash plus $10M.","Pre-merger Imara stockholders to own ~16% of combined co; CVRs tied to asset sale/IMR-261.","Concurrent $164.5M Enliven PIPE; closing conditioned on Imara asset sale, HSR, stockholder votes.","Board: 8 Enliven designees, 1 Imara (CEO Rahul Ballal); reverse stock split planned.","Termination fees: Imara pays $3M, Enliven pays $9.75M under specified conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-262210","json":"https://secwatch.observer/filing/0001193125-22-262210.json","markdown":"https://secwatch.observer/filing/0001193125-22-262210.md","text":"https://secwatch.observer/filing/0001193125-22-262210.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672619/000119312522262210/0001193125-22-262210-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672619/000119312522262210/d343665d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T03:51:26.432992+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}